New biomarkers for diagnosing inflammatory bowel disease and assessing treatment outcomes Academic Article uri icon


MeSH Major

  • Adenocarcinoma
  • Adenoma
  • Colonic Polyps
  • Inflammatory Bowel Diseases
  • Intestinal Neoplasms
  • Precancerous Conditions


  • Despite advances in our understanding of the pathophysiology underlying inflammatory bowel disease, there remains a significant need for biomarkers that can differentiate between Crohn's disease and ulcerative colitis with high sensitivity and specificity, in a cost-efficient manner. As the focus on personalized approaches to the delivery of medical treatment increases, new biomarkers are being developed to predict an individual's response to therapy and their overall disease course. In this review, we will outline many of the existing and recently developed biomarkers, detailing their role in the assessment of patients with inflammatory bowel disease. We will identify opportunities for improvement in our biomarkers, including better differentiation between the subtypes of inflammatory bowel disease. We will also discuss new targets and strategies in biomarker development, including combining modalities to create biomarker signatures to improve the ability to predict disease courses and response to therapy among individual patients.

publication date

  • December 2016



  • Academic Article



  • eng

PubMed Central ID

  • PMC5345848

Digital Object Identifier (DOI)

  • 10.1097/MIB.0000000000000903

PubMed ID

  • 27763951

Additional Document Info

start page

  • 2956

end page

  • 2965


  • 22


  • 12